Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
3. Cita con resumen
Whittle J. Blood pressure variability and cardiovascular risk. BMJ 2016;354:i4190. [Ref.ID 100604]
4.Tiene citas relacionadas Cita con resumen
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodríguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright Jr JT, Pajewski NM, for the SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged =75 years: a randomized clinical trial. JAMA 2016;315:2673-82. [Ref.ID 100474]
5.Tiene citas relacionadas
Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the finish. N Engl J Med 2015;373:2174-5. [Ref.ID 99776]
6.Tiene citas relacionadas Cita con resumen
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2013-6. [Ref.ID 99661]
7. Cita con resumen
Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of results from the Systolic Blood Pressure Intervention Trial (SPRINT) to the US adult population . J Am Coll Cardiol 2015:9 de noviembre. [Ref.ID 99635]
8.
Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011;343:1060-3. [Ref.ID 91842]
9.Tiene citas relacionadas
Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011;364:1272-4. [Ref.ID 90526]
10.Tiene citas relacionadas Cita con resumen
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, for the HCV RESPOND-2 Investigators. Boceprevir chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-12. [Ref.ID 90524]
11.Tiene citas relacionadas Cita con resumen
Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P, for the SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. [Ref.ID 90523]
12.
van der Elst ME, Buurma H, Bouvy ML, de Boer A. Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother 2003;37:1465-77. [Ref.ID 67646]
13. Cita con resumen
Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E, for the SPRINT Study Group. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-53. [Ref.ID 37632]
Seleccionar todas
 
 1 a 13 de 13